@entity302 in XXXX 1.

@entity1 @entity3877 @entity1032 @entity410 @entity66 @entity5 @entity75 @entity600 @entity6795 @entity5150 @entity4207 @entity302 @entity4786
@entity4786 1 is the most common @entity66 . Neurologic manifestations are mainly represented by @entity5 such as @entity5150 , focal areas of high T2-weighted signal known as unidentified bright objects, and @entity1032 or @entity4207 . The prevalence of @entity410 has been reported to range from 3.8 to 6%. In the present study, we evaluated prevalence, type, and etiology of @entity302 in a @entity4786 1 population. A retrospective analysis of 198 @entity1 affected by @entity4786 1 was performed. Fourteen @entity1 (7%) were found to be @entity302 . Every @entity1 underwent electroencephalographic examination and neuroimaging investigations. Thirteen were submitted to magnetic resonance imaging (MRI) study and one to computed tomographic (CT) scanning. Single-photon emission computed tomographic and positron emission tomographic studies were performed in a few selected cases. @entity410 were partial in 12 of these (85%) and generalized in 2 (15%). In nine (64%), @entity302 was secondary to @entity75 : five of these had @entity5 (three with @entity302 as the fist symptom), three had cortical @entity600 , and one had @entity3877 . @entity410 were controlled rapidly in eight (57%) and drug resistant in four (29%). Two @entity1 were lost at follow-up. All @entity1 with uncontrolled @entity410 had severe @entity1032 , and three of these had @entity6795 . Our observations and our re-evaluation of the literature indicate that @entity1 with @entity4786 1 have an increased risk of @entity302 related to intracranial masses and @entity410 can represent the first symptom of a @entity5 or cortical @entity600 . Brain MRI and, in selected cases, functional studies appear to be useful in @entity1 with @entity4786 1 who present with @entity410 , especially if associated with @entity1032 .
